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Abstract: Mass-sensing biosensor arrays for protein detection require no fluorophores or enzyme 
labels.  However, few mass biosensor protein arrays have demonstrated successful application in 
high background samples, such as serum.  In this paper, we test the BioCD as a mass biosensor based 
on optical interferometry of antibodies covalently attached through Schiff-base reduction.  We use 
the BioCD to detect prostate specific antigen (PSA, a biomarker of prostate cancer) in patient sera in a 
96-well anti-PSA microarray.  We have attained a 4 ng/ml detection limit in full serum and have 
measured PSA concentrations in three patient sera. 
 
Introduction 
The development of mass-sensing biosensors (without the need for fluorophore labeling, 
radiolabels or other chemicals) for protein detection is advancing rapidly.  Surface plasmon 
resonance (SPR) [1, 2], imaging ellipsometry [3, 4], photonic gratings [5], BioCD [6-9], 
nanowires [10], and micro-cantilevers [11, 12] have been proposed and demonstrated in 
succession.  These biosensors sense the mass of biomaterial and have the potential for 
high-throughput and quantitative protein detection.  Methods such as Western blot or 
enzyme-linked immunosorbent assay (ELISA) detect specific protein via fluorescence or other 
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chemically-induced signals.  These signals are assumed to be proportional to the amount of 
target protein.  However, the intensity of fluorescence and the chemically-induced signals may 
be adversely affected by other parameters such as the local electrical field intensity, pH, 
temperature, or may be subject to bleaching and quenching.  On the other hand, mass 
biosensors measure protein quantity by directly converting the protein mass into physical signals 
which are more independent of the local micro-environment.  For example, SPR, ellipsometry 
and the BioCD convert protein mass into optical quantities (surface plasmon, polarization and 
light intensity, respectively).  Nanowires and micro-cantilivers convert protein mass into 
electrical and mechanical quantities, respectively.  Among these mass biosensors, the BioCD 
converts protein mass on a SiO2/Si wafer into a reflectance variation via local interferometry 
which optimizes the protein signal under a quadrature condition [6].  The large area of the wafer 
can accommodate thousands of assays simultaneously.  SiO2/Si wafers can be obtained 
economically, and the SiO2 modification has been extensively studied for protein immobilization.  
In addition, the BioCD scanning system adopts a spinning-disc approach which reduces the 
detection noise floor and improves protein detection limits [13].  The detection resolution for 
average protein layer thickness can be as small as 2 pm for a single 150 micron-diameter protein 
spot. 
 Protein array mass biosensors face obstacles in clinical applications because the background 
protein level in serum is much higher than the target protein concentration and induces strong 
non-specific binding.  Non-specific binding can mask the target signal because label-free 
biosensors detect all protein present rather than only the specific target protein.  In this report, 
we adopted an enhanced Schiff-base method to produce butyraldehyde-modified silicon wafers 
for an antibody microarray that significantly suppresses the non-specific binding.  The high 
sensitivity of the BioCD combined with stable surface chemistry allows us to detect the target 
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protein at ng/ml levels in a high protein background, such as serum (total protein level >40 
mg/ml [14]). 
 
Experimental Methods 
Principle of the BioCD.  The BioCD has the format of a disc with dielectric coatings.  
The coatings create a surface reflection coefficient  and reflectance r 2| |R r= .  After a protein 
layer is immobilized on the coating surface, the reflectance is changed to 'R .  We have shown 
previously [15] that the reflectance increment caused by protein, 'R R RΔ = − , has an explicit 
relation to the original , expressed by r
( )2 2
0
2Im 1 ( 1)
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dR r r n πλ θ⎡ ⎤Δ = + −⎣ ⎦        (1) 
where  is the refractive index of the protein layer,  is the thickness of the protein layer, pn d λ  
is the wavelength of the probe light, and 0θ  is the incident angle.  A laser scans the disc, 
measuring the height (or mass area density) of printed protein.  For a defined protein layer and 
probe wavelength, where , , pn d λ  and 0θ  are constants, RΔ  is maximized when 
.  A silicon wafer with 120 nm of thermal SiO0.577r = ± i
i
2 has a calculated 
 at a wavelength of 488 nm with s-polarization and 300.049 0.489r = − + o incidence, which is 
near the optimal value for .  This working condition has only one dielectric layer (SiOr 2).  
On this 120 nm SiO2 wafer, a 1 nm protein layer induces 0.0056 absolute reflectance change, or 
2.3% relative intensity increment.  We use a spinning disc scanning system to acquire the 
reflectance map of the entire disc, which is converted into a map of protein areal density or 
protein layer height. 
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Scanning system.  The experimental layout of the BioCD scanning system is shown in Fig. 
1.  The probe light is incident at 30º on the disc with s-polarization, although unpolarized 
normally-incident light works as well because interferometry does not require polarization 
analysis.  The light source is an INNOVA 300 Argon laser (Coherent, Inc.) using a wavelength 
of 488 nm.  The reflectance signal of the BioCD is detected by a silicon-based detector.  The 
BioCD is mounted on a motor (Lincoln Laser, Inc.) on a linear translation stage (MM2000, 
Newport Corp).  2D scanning is realized by spinning the motor and moving the stage.  A 
computer controls the entire system, collects the reflectance data and reconstructs the reflectance 
map of the entire BioCD with a resolution of 20 μm.  One scan of a 100 mm diameter BioCD is 
completed in one hour. The reflectance map is converted to a protein thickness profile using the 
conversion ratio , where  ( ) / / 0.023d nm R R= Δ R  is the background reflectance, and RΔ  is 
the reflectance change caused by the protein layer. 
Surface Chemistry.  The 120 nm thermal oxide on silicon was aldehyde-functionalized to 
bind protein covalently.  Butyraldehyde was grafted on the SiO2 surface through silanization 
where the silanol group (Si-OH) on the aldehydic silane reacts with a hydroxyl group (-OH) on 
hydrated silica surface and forms a disiloxane bond(Si-O-Si).  The antibodies are printed on the 
functionalized silica surface by a protein printer.  The carbonyl group of butyraldehyde reacts 
with the amino groups of the antibody to form a Schiff base [16], a carbon-nitrogen double bond 
which immobilizes the antibody molecules through primary amines.  After antibody printing, 
the surface was reduced by a NaBH4 solution which stabilizes antibody attachment by converting 
carbon-nitrogen double bond (C=N) to carbon-nitrogen single bond (C-N).  The NaBH4 also 
helps to block the substrate by reducing remnant carbonyl groups to hydroxyl groups.  The 
BioCD is further blocked by casein solution (Phosphate buffered saline (PBS) + 1% casein 
solution in 20:1 volume ratio, PH 8.0), washed by 50 mM citric acid solution (PH 6.0), PBST 
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(PBS + 0.05% Tween 20) and deionized water and spun dry at 1000 rpm.  Bovine serum 
albumin (BSA) is widely used for surface blocking in many antibody microarrays, but it is not 
recommended for the mass-sensing BioCD because BSA is a large protein molecule which 
contributes more mass noise for interferometric biosensors.  Here, we use casein for its small 
molecular weight. 
Prostate Specific Antigen (PSA). We applied the BioCD to detect PSA levels in prostate 
cancer patient sera. PSA is a member of the kallikrein family exclusively produced by the 
prostate gland.  It has a concentration of 0.5 mg/mL to 2.0 mg/mL in normal seminal fluid [17, 
18] and 0 to 4 ng/ml [19] in normal serum.  Prostate cancer and other prostate pathological 
changes may cause PSA to leak into the peripheral circulation and induce an abnormal elevation 
of PSA in serum.  Levels higher than 4 ng/ml may suggest the presence of prostate cancer.  
Therefore PSA can work as a biomarker for prostate cancer.  Measurement of PSA in serum is 
one of the standard diagnostics for prostate cancer and is usually performed by ELISA.  There 
has been no previous study showing successful PSA measurement in patient sera based on 
mass-sensing biosensors in a microarray format. 
96-well BioCD.  We print antibody and reference protein in the format of paired target and 
reference spots on the BioCD and perform a prescan to record the initial height of all protein 
spots.  During analyte solution incubation, antibodies capture target antigen due to 
immuno-binding, and the height of the antibody spot increases.  A postscan is performed to find 
the protein spot heights after the assay.  The specific height increment is defined as the antibody 
increment minus the reference-spot increment.  If nonspecific binding is similar to both spots, 
then this procedure subtracts this background contribution.  The difference is then related to the 
antigen concentration in the sample.  Together—printing antibody, a prescan, incubation of 
analyte solution followed by a second specific antibody, and a postscan—complete one assay.  
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To perform multiple assays simultaneously on a single BioCD, the surface of a 100 mm diameter 
disc is separated into 96 wells with ultra-hydrophobic surface pads shown in Fig. 2 a), b) and c).  
The contact angle of water on the pads is as large as 90o to confine the incubation solution within 
each well, and 96 assays can be performed in parallel on a single disc.  The 96-well BioCD 
enables multiple sample tests or multiplexed protein detection, respectively, by incubating with 
different samples or by printing multiplexed antibodies in wells.  Fig. 2 shows the prescan of a 
96-well anti-PSA BioCD used in the following experiment.  The protein mass profile in 
thickness is derived from the reflectance map and recorded for each well shown in Fig. 2d).  An 
assay example is shown in Fig. 3 in which a negative and a positive response were observed, 
respectively, for 0 and 1 μg/ml analyte incubation. 
PSA Detection in Patient Sera. We applied the 96-well anti-PSA BioCD to PSA detection in 
patient sera.  A Scienion (BioDot Corp.) piezoelectric printer was used to print 32 antibody 
spots (affinity purified polyclonal anti-PSA produced in goat, G-126-C, Biospacific Co.) and 32 
reference spots (anti-rabbit IgG produced in goat, R2004, Sigma Inc.) in each of the 96 wells on 
a butrylaldehyde-activated BioCD.  The diameter of each spot was approximately 150 μm with 
a spot-to-spot separation of approximately 300 μm.  Each antibody spot is locally paired with a 
reference spot in a format as shown in Fig. 2 d).  A prescan was performed to record the 
original protein profile of the entire BioCD after printing. 
Test samples included: 1) female serum (PSA level is null in female serum so it is a negative 
control), 2) PSA spiked into female serum, and 3) prostate-cancer patient sera.  The three 
patient sera were acquired from the Purdue Cancer Center.  The PSA concentrations had been 
measured with ELISA to be 34, 117 and 2138 ng/ml respectively for samples 1, 2 and 3.  
Female serum was purchased from Innovative Research, Inc.  Affinity purified PSA reagent 
was purchased from Fitzgerad Co. 
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We created a series of PSA-spiked female sera with PSA concentrations 0, 4, 12.6, 40, 126, 
400, 1260, 4000, and 12640 ng/ml.  The PSA-spiked serum was used to generate a standard 
PSA response curve.  For all three patient sera, we performed a series dilution in 
half-logarithmic sequential ratios 1:1, 1:3.16, 1:10, 1:31.6, 1:100 diluted by female serum (the 
ratio 1:m is defined as 1 patient serum + m-1 female serum).  Dilution with female serum 
instead of buffer solution maintains an equal protein background for all test samples. 
Prior to incubation, all samples were diluted by PBST solution in a ratio 1:4.  This step is 
crucial because Tween-20 in the buffer suppresses non-specific binding.  All samples shared the 
same protein background level (i.e., 1/4 of full human serum) at about 10 mg/ml.  Patient sera 
dilution ratios then became 1:4, 1:12.6, 1:40, 1:126 and 1:400.  PSA concentrations in spiked 
female serum became 0, 1, 3.16, 10, 31.6, 100, 316, 1000, 3160 ng/ml.  We incubated the 
96-well anti-PSA BioCD with these prepared samples.  Each sample was distributed across 4 
randomly allotted wells to suppress local bias on the disc.  Overall, 9×4 wells were used for 
PSA spiked serum to acquire the standard response curve and 3×5×4 wells were used for diluted 
patient sera to acquire the curves for sequential dilution.  The incubation time was 1 hour, after 
which the BioCD was washed for 5 min with PBST and 5 min with DI water (on an orbital 
shaker) and dried with pure nitrogen.  After this procedure, PSA molecules in the samples had 
been captured by the anti-PSA spots on the BioCD. 
Sandwich assays were performed to amplify the assay response through the added mass of 
the second antibody.  All 96 wells were incubated with 10 μg/ml anti-PSA (G-126-C, 
Biospacific Co.) in PBST for 30 min (static incubation), followed by 5 min PBST and 5 min DI 
water wash (on orbital shaker), and dried with pure nitrogen.  The anti-PSA antibodies bind 
with the captured PSA antigen and amplify the antibody spot height increment in the assays.  A 
postscan was performed to record all protein spot heights after the sandwich incubation. 
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 Results and Discussions 
The immunoassay responses in all wells were computed from the prescan and postscan data 
of the 96-well BioCD reflectance map (with a resolution of 20 μm).  An image analysis 
program automatically located all wells on the map, extracted protein spot profiles for each well 
and calculated the pre- and post-height of all 6144 spots.  The assay response was then 
calculated for each pair of antibody and reference spots by the algorithm (postH-preH)antibody - 
(postH-preH)reference.  The analysis can be completed in less than 10 minutes on a desktop 
computer. 
Evaluation of the Detection Limit for PSA.  We evaluated the limit of detection (LOD) 
for PSA by comparing the assay responses for 0, and 1 ng/ml PSA spiked sera presented in Fig. 
4a (LOD evaluation).  The error bars represent the standard error of the assay variation for each 
test sample using 128 spots as the spot population number (4 replicate wells).  The assay 
response is 0.007 nm for 0 ng/ml PSA spiked female serum as a negative control sample and 
0.039 nm for 1 ng/ml PSA spiked female serum.  The standard errors of the tests are 
respectively 0.0094 nm and 0.0078 nm.  Using a 3σ criterion for a positive response, 
0.039-0.007 = 0.032 (nm) is larger than three times the standard error 0.0094 nm, making the 
assay response positive at 1 ng/ml in PSA-spiked female serum (1:4 dilution of full serum)  
with a background of about 10 mg/ml.  The detectable PSA level is 0.1 ppm of the background 
concentration.  Therefore, the 1 ng/ml detection limit in 1:4 serum is equivalent to 4 ng/ml in 
full serum, which is the clinical threshold for prostate cancer diagnosis. 
PSA Concentration recovery in patient sera.  A standard PSA response curve was 
generated from the assays of PSA-spiked female sera.  The dilution curves of patient samples 
were acquired from sequentially-diluted samples.  We measured the PSA levels in the patient 
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sera by matching the effective concentrations of the dilution series 
Both the standard response and the dilution curves are fit by the Langmuir equation [20] 
[ ]
[ ]Satur D
PSAH H
PSA K
= +  and Satur C
DH H
D D
= +  where D is the dilution ratio, DK  is the 
equilibrium constant, and  is the central dilution ratio at which the assay response is the half 
of the saturated response.  
CD
DK  and  are calculated by fitting the standard response curve 
and the dilution curves of the patient samples.  Because  is the dilution ratio at which the 
diluted sample has the same assay response as a sample with an analyte concentration equal to 
CD
CD
DK , the analyte concentration in the test sample is recovered as the ratio /D CK D . 
The standard response curve and patient sera dilution curves are shown in Fig. 4 a) and b).  
DK  was found to be 15.8 ng/ml, and the  are 0.51, 0.32 and 0.0033, respectively, for patient 
serum samples 1, 2 and 3.  The recovered PSA concentrations are 15.8/0.51 = 31 (ng/ml) for 
sample 1, 15.8 /0.32 = 49 (ng/ml) for sample 2 and 15.8/0.0033 = 4788 (ng/ml) for sample 3.  
PSA levels in the three samples were measured previously as 34, 117 and 2138 ng/ml by ELISA.  
CD
 
Conclusions 
We have demonstrated a mass-sensing biosensor capable of measuring a low-level cancer 
biomarker in patient sera.  Mass-sensing biosensor protein arrays have been challenged by 
strong non-specific binding caused by the high protein background in serum.  Currently, few 
mass-sensing biosensor protein arrays successfully detect target protein in serum or other body 
fluids and therefore are excluded from clinical application.  To suppress the non-specific 
binding, we used a reference-spot subtraction analysis plus Schiff-base reduction and casein 
blocking.  For incubation, we added 0.05% Tween 20 into analyte solution to further suppress 
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non-specific binding.  Moreover, the locally-paired reference spot for each antibody spot helped 
to monitor and neutralize the local non-specific binding.  The large population of antibody spots 
further reduced the detection error. The combination of these factors has allowed us to 
successfully perform PSA detection in prostate cancer patient sera.  We found a 1 ng/ml PSA 
detection limit in PSA-spiked serum with 10 mg/ml background.  This detection limit is 
equivalent to 4 ng/ml PSA in full serum ,which is the threshold for normal-to-abnormal PSA 
levels.  We also recovered the PSA concentrations for three patient serum samples at 31, 49 and 
4788 ng/ml compared with 34, 117 and 2138 ng/ml measured by traditional enzyme-labelled 
ELISA.  The results suggest that the combination of the BioCD interferometric laser scanning 
with the enhanced Schiff base chemistry has the potential for clinical applications. 
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Fig. 1. BioCD Scanning system.  This system scans the BioCD and acquires a 2D reflectance map with 20 
μm resolution.  Probe light with 488 nm wavelength is obliquely incident to achieve an optimal 
interferometric condition for protein sensing. 
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Fig.2. Imaging of protein profiles on a 96-well BioCD.  A) and B) 96 wells were isolated and numbered with 
ultra-hydrophobic ink on a thermal-oxide silicon wafer with 120 nm SiO2.  C) Antibody and reference spots 
were printed in wells in an 8x8 spot pattern consisting of 2x2 unit cells of two target and two reference spots.  
Incubation solution is confined within each single well by the hydrophobic boundary allowing multiple sample 
tests performed on a single BioCD.  D) Protein spot mass profile (in terms of protein layer height in units of 
nm) of each well is derived from the reflectance map. 
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Fig.3. Demonstration of two well-based sandwich assays at 0 ng/ml and 1000 ng/ml.  A prescan was 
performed before the assays to record the original height of the protein spots.  After the sandwich assays, a 
postscan recorded the new protein heights.  For the well incubated with 0 ng/ml PSA spiked serum, the 
average specific increment is 0.007 nm, and for the well incubated by 1000 ng/ml PSA spiked serum, the 
increment is 0.18 nm. 
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Fig.4. PSA concentration recovery for three patient samples.  We compared and matched the dilution 
curves shown in Fig. b) with the standard response curve in Fig. a) to find the concentration of PSA in the 
patient sera.  The standard curve was acquired from the assay results based on a series of PSA-spiked female 
sera and fit by a Langmuir equation.  The equilibrium constant KD was 15.8 ng/ml for PSA in serum.  The 
central dilution ratios DC were 0.51, 0.32, and 0.0033 for the three patient samples.  The PSA concentrations 
are calculated as [PSA]=KD /DC and are 31, 49, 4788 ng/ml respectively for sample 1, 2 and 3.  The PSA 
levels measured by ELISA in these three samples were 34, 117 and 2138 ng/ml. 
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